Pharmaceutical

WuXi debates sale of pharma operations as BIOSECURE Act advances

WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.

Oct 6, 2024 - 04:00
WuXi debates sale of pharma operations as BIOSECURE Act advances
WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.
Read the original article

Tags:

Previous Article

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

Next Article

The benefits of using a nimble platform from phase to phase

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CymaBay seeks FDA approval for primary biliary cholangitis therapy

CymaBay seeks FDA approval for primary biliary cholangi...

Dec 18, 2023

NICE supports Theramex’s Eladynos for post-menopause osteoporosis

NICE supports Theramex’s Eladynos for post-menopause os...

Aug 11, 2024

NUHS’s CD7 CAR-T cell therapy shows promise for leukaemia

NUHS’s CD7 CAR-T cell therapy shows promise for leukaemia

Oct 8, 2024